New antiepileptic drug safety information is not transmitted systematically and accepted by U.S. neurologists

Epilepsy and Behavior

Volumn 29, Issue 1, 2013, Pages 36-40

  Bell, Sarah G ^a   Matsumoto, Martha ^a   Shaw, Susan J ^b   Brandt, Jason ^a   Krauss, Gregory L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Antiepileptic drugs; Error in medicine; Methods of education; Patient safety; Professional conduct and ethics

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; VALPROATE SEMISODIUM;

ADULT; AGED; ARTICLE; ASIAN; BIRTH DEFECT; CLINICAL PRACTICE; COGNITIVE DEFECT; CONGENITAL MALFORMATION; DRUG HYPERSENSITIVITY; DRUG INFORMATION; DRUG SAFETY; E-MAIL; FEMALE; HAPLOTYPE; HEALTH CARE SURVEY; HUMAN; KNOWLEDGE; MALE; NEUROLOGIST; NORMAL HUMAN; RISK FACTOR; SCREENING TEST; SUICIDE; UNITED STATES;

ANTIEPILEPTIC DRUGS; ERROR IN MEDICINE; METHODS OF EDUCATION; PATIENT SAFETY; PROFESSIONAL CONDUCT AND ETHICS;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANALYSIS OF VARIANCE; ANTICONVULSANTS; ATTITUDE OF HEALTH PERSONNEL; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLOGY; PHYSICIANS; UNITED STATES;

EID: 84882666113     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2013.06.008     Document Type: Article

References (19)

1. U.S.Food and Drug Administration Drug safety communications Available at:, [Accessed July 19, 2012]. http://www.fda.gov/drugs/drugsafety/ucm199082.htm.
2. Duestzina S.B., Higashi A.S., Dorsey E.R., Conti R., Huskamp H.A., Zhu S., et al. Impact of FDA drug risk communications health care utilization and health behaviors. Med Care 2012, 50:466-478.
3. Cluston R.J., Li Z., Heaton P.C., Weiss S.R., Zuckerman I.H., Moomaw C.J., et al. Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program. Pharmacoepidemiol Drug Saf 2005, 14:1-9.
4. Graham D.J., Drinkard C.R., Shatin D., Tsong Y., Burgess M.J. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001, 286:831-833.
5. Wagner A.K., Chan K.A., Dashevsky I., Raebel M.A., Andrade S.E., Lafata J.E., et al. FDA drug prescribing warnings: is the black box half empty or half full?. Pharmacoepidemiol Drug Saf 2006, 15:369-386.
6. U.S.Food and Drug Administration Information for healthcare professionals: suicidal behavior and ideation and antiepileptic drugs Available at:, [Accessed May 14, 2012]. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm100192.htm.
7. Wyszynski D.F., Nambisan M., Surve T., Alsdorf R.M., Smith C.R., Holmes L.B. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005, 64:961-965. [serial online].
8. Meador K.J., Baker G.A., Browning N., Clayton-Smith J., Combs-Cantrell D.T., Cohen M., et al. Cognitive function at 3years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009, 360:1597-1605.
9. Alfirevic A., Jorgensen A.L., Williamson P.R., Chadwick D.W., Park B.K., Pirmohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006, 7:813-818.
10. Hesdorffer D.C., Kanner A.M. The FDA alert on suicidality and antiepileptic drugs: fire or false alarm?. Epilepsia 2009, 50(5):978-986.
11. FDA Alert Information for healthcare professionals: dangerous or even fatal skin reactions - carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics) Available at:, [Accessed May 29, 2012]. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124718.htm.
12. Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review 2009, Abbott Pharmaceuticals PR Ltd., North Chicago (IL), [Package insert. NDC 0074-6212-13].
13. Neurologists AAN member demographics Available at:, [Accessed April 10, 2012]. https://www.aan.com/globals/axon/assets/6723.pdf.
14. Shneker B.F., Cios J.S., Elliott J.O. Suicidality, depression screening, and antiepileptic drugs: reaction to the FDA alert. Neurology 2009, 72:987-991.
15. Busch S.H., Frank R.G., Leslie D.L., Martin A., Rosenheck R.A., Martin E.G., et al. Antidepressants and suicide risk: how did specific information in FDA safety warnings affect treatment patterns?. Psychiatr Serv 2010, 61:11-16.
16. Smalley W., Shatin D., Wysowski D.K., Gurwitz J., Andrade S.E., Goodman M., et al. Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. JAMA 2000, 284:3036-3039.
17. Haneef Z., Stern J., Dewar S., Engel J. Referral pattern for epilepsy surgery after evidence-based recommendations. Neurology 2010, 75:699-704.
18. Klabunde C.N., Frame P.S., Meadow A., Jones E., Nadel M., Vernon S.W. A national survey of primary care physicians' colorectal cancer screening recommendations and practices. Prev Med 2003, 36:352-362.
19. Pellock J.M., Faught E., Sergott R.C., Shields W.D., Burkhart G.A., Krauss G.L., et al. Registry initiated to characterize vision loss associated with vigabatrin therapy. Epilepsy Behav 2011, 22:710-717.